VIDEO: Rebyota effective in prevention of recurrent C. diff , even in higher risk patients
PHILADELPHIA — Rebyota was safe and effective at 8 weeks and up to 6 months in patients with recurrent Clostridioides difficile infection, many of whom had other gastrointestinal comorbidities and risk factors, according to data presented. “We showed a significant decrease in recurrence rates of Clostridioides difficile in a real-world population,” Timothy E. Ritter, MD, a